Effect of antiviral therapy on prognosis of patients with decompensated cirrhosis

Yubo HUANG,Yong QIAO,Lusi CHANG,Xiaohua HAO,Fan XIAO,Honglian WEI,Renwen ZHANG,Jun CHENG,Hongshan WEI

DOI: https://doi.org/10.3969/j.issn.1006-5709.2011.04.012

2011-01-01

Abstract:Objective To observe the effect of antiviral therapy on the survival time of patients with decompensated liver cirrhosis and occurrence of hepatocellular carcinoma(HCC).Methods All of the subjects(237 cases) were diagnosed as patients with decompensated cirrhosis from January 1998 to December 2009,received treatment at Beijing Ditan Hospital at least 3 times or more.All of the subjects died during his/her last hospitalization.Subjects included 168 males and 69 females.29.54%(70/237) patients received at least 6 months anti-viral therapy.Drug resistance was determined by PCR amplification and sequencing method.Results The survival time of patients receiving antiviral therapy(34.44±28.39 months) was significantly longer than that of untreated patients(27.12±24.29 months).All of 167 patients without receiving antiviral therapy,35.93%(60/167) patients were diagnosed as liver cancer before death;28.57%(20/70) patients receiving antiviral treatment were diagnosed as liver cancer before death.There was no statistically significant difference of incidence rate of liver cancer between two groups(P=0.37).There were 6 patients developing drug-resistance,but no disease aggravation was observed.Conclusion Antiviral therapy may help to prolong survival time of patients with decompensated cirrhosis,but can not reduce the incidence of liver cancer.